Level-1 Data From the REDUCE Study and the PCPT Data
October 2015
in “
Prostate Cancer
”
TLDR Finasteride and dutasteride reduce prostate cancer risk, but finasteride may increase higher-grade cancer risk.
The document discussed two major studies evaluating 5-alpha-reductase inhibitors for prostate cancer risk reduction. The Prostate Cancer Prevention Trial found that finasteride significantly reduced prostate cancer detection risk in men with low PSA levels, but increased higher-grade disease diagnoses. The REDUCE trial assessed dutasteride in men with elevated PSA levels, showing significant prostate cancer risk reduction without increasing higher-risk disease compared to placebo.
